Filgotinib On Uncertain Path As Gilead Regains Speed From Pandemic Hit
Oncology Shines And Antivirals Recover In Q3
Third quarter earnings show Gilead’s Immunomedics buy paid off, but filgotinib’s path may narrow. The HIV and HCV franchises picked up from their COVID-19 lull.
You may also be interested in...
Gilead’s Lenacapvir May Offer Twice-Yearly HIV Salvage Therapy
A first-in-class capsid inhibitor for HIV, lenacapavir has produced strong efficacy data for viral load reduction in treatment-experienced patients. The data measure up well against Viiv’s Rukobia, analyst says.
Viiv’s Cabotegravir Shows Superiority Over Truvada as PrEP Among Women
ViiV unblinded the Phase III study on positive data, and it plans to pursue approval in H1 2021.
Veklury Takes Gilead Earnings On Wild Ride
The company is narrowing its 2020 guidance, citing COVID-19’s unpredictability and its effects on Veklury’s sales.